354 results on '"DeWeese, T.L."'
Search Results
2. The Impact of TP53 Mutations and Use of the TP53-Mutation-Reactivating Agent APR-246 on Metastatic Castrate-Sensitive Prostate Cancer
3. Prospective Characterization of Circulating Tumor Cells in Hormone Sensitive Oligometastatic Prostate Cancer Patients on a Metastasis-Directed Therapy Trial
4. Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer
5. Defining the Transcriptional Landscapes of the Tumor Microenvironment of Cervical and Vaginal Cancers at Single-Cell Resolution
6. Sexual Function and Dosimetric Relationships to Erectile Structures among Patients Treated Definitively with Pd-103 LDR Prostate Brachytherapy
7. Evaluation of Psychiatric Diagnoses as a Source of Bias in Prognostication and Decision-Making for Palliative Radiotherapy
8. On-Treatment Hematological Markers are Associated with Increased Hospitalization and Emergency Department (ED) Visits in Head and Neck Squamous Cell Carcinomas (HNSCC)
9. Lymphocyte Kinetics is an Important Prognosticator in Predicting Survival Outcomes for Head and Neck Squamous Cell Carcinoma (HNSCC) Patients Using a Ransom Survival Forest (RSF) Model
10. Development of a Reactive Stroma Gene Signature (RSGS) Score to Characterize the Longitudinal Cellular and Molecular Alterations in the Tissue Microenvironment of Locally Advanced Cervical Cancer in Response to Radiotherapy at Single-Cell Resolution
11. Phase II Randomized Study of Salvage Radiation Therapy (SRT) plus Enzalutamide or Blinded Placebo for High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy: The SALV-ENZA Trial
12. Role of WNT Pathway Mutations within Oligometastatic Castration-Sensitive Prostate Cancer
13. Evaluating and Optimizing Prognostic Modeling for Patients Undergoing Stereotactic Body Radiotherapy for Bone Metastases
14. Assessment of Circulating Tumor Cells in Oligometastatic Castration-Sensitive Prostate Cancer Patients from the ORIOLE Trial
15. Outcomes of RAdium-223 and SABR vs. SABR for oligomEtastatic prostate caNcerS – The RAVENS Phase II Randomized Trial
16. Magnetic field generating inductor for cancer hyperthermia research
17. Radiotherapy Deserts: Impact of Race, Poverty and the Rural-Urban Continuum on Density of Radiation Oncologists in the United States
18. Initial Impact and Operational Response of Radiation Oncology Practices to the COVID-19 Pandemic in the United States, Europe, and Latin America
19. External Validation of the Bone Metastases Ensemble Trees for Survival (BMETS) Machine Learning Model to Improve Estimation of Life Expectancy
20. Metastasis Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer
21. Establishing the Prevalence of Complicated Bone Metastases in Community Radiation Oncology Clinics
22. Modes of Failure Following Metastasis Directed Therapy in Patients with Oligometastatic Hormone Sensitive Prostate Cancer: A Multi-institutional Analysis
23. Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE)
24. Stereotactic Ablative Radiation and Short-Term Androgen Ablation for Intermediate-Risk Localized Prostate Adenocarcinoma: Safety and Toxicity From a Prospective Single-Arm Phase II Trial (NCT01517451)
25. Clinical Outcomes in Oligometastatic Prostate Cancer Following Definitive Radiation Therapy
26. Establishing an American Sign Language (ASL) Inclusive Residency Training Program
27. Development and Validation of the First AJCC Compliant Clinical Staging System for Localized Prostate Cancer: Results from a Multicenter International Study
28. Pilot Assessment of the BMET Decision Support Platform: A Tool to Improve Provider Survival Estimates and Selection of Prognosis-Appropriate Treatment for Patients with Symptomatic Bone Metastases
29. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost: Comparison of Outcomes in A Multi-Institutional Analysis of 4,086 Patients with High-Risk Prostate Cancer
30. Circulating Tumor DNA Is an Accurate Measurement of Determining Radiation-Induced Therapeutic Response and Tumor Burden Monitoring in a Prostate Cancer Bone Metastases Murine Model
31. Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer
32. Optimized Survival Evaluation to Guide Bone Metastases Management: Developing an Improved Statistical Approach
33. Hydroxyflutamide Induces Androgen Receptor-Mediated DNA Damage and Radiosensitizes Prostate Cancer Cells While Preventing Induction of Pro-Growth Programs
34. Use of Relational Coordination Scale to Assess Perceptions of Physician Teamwork Skills by Clinical and Administrative Staff
35. Comparison of Prospectively-Collected Physician-Reported and Patient-Reported Toxicities Among Gynecological Cancer Patients Receiving Radiation Therapy
36. Analysis of the Correlation between Incident Learning System Reporting and Patient Care Experience through Process Map Analysis for Clinical Workflow Improvement
37. SABR Produces Systemic Adaptive Immune Responses in Castration-Sensitive Oligometastatic Prostate Cancer Patients
38. Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer
39. PSMA-Directed Biologically-Guided Radiation Therapy of Castration-Sensitive Oligometastatic Prostate Cancer Patients
40. A Comparison of Prospectively Collected Genitourinary and Gastrointestinal Toxicities and Dose Volume Histogram in Patients Treated with Intensity-Modulated Radiation Therapy or Non-Intensity-Modulated Post-Operative Radiation Therapy
41. Intraoperative Dynamic Dosimetry Using Registered Ultrasound and Fluoroscopy Improves Prostate Brachytherapy Dose Coverage Without Increasing Dose to Normal Tissues
42. Radiation myositis
43. Patterns of Errors and Incidents Reported in a Regionally Expanding Academic Radiation Oncology Department
44. Differences in Compensation Between Men and Women at United States Public Academic Radiation Oncology Departments
45. Successful Adoption of an Incident Learning Systems in a Regionally Expanding Academic Radiation Oncology Department
46. Risk Tolerance in Radiation Oncology: A Multi-Institutional Survey
47. Comparison of Prospectively-Collected Genitourinary and Gastrointestinal Toxicities Between Post-Operative Intensity-Modulated Radiation Therapy and Non-Intensity-Modulated Radiation Therapy Patients
48. Changes in Radiotherapeutic Management of Prostate Cancer Following PSMA-based 18 F-DCFPyL PET Imaging: A Snapshot of Prospective Trials at a Single Institution
49. End-of-Treatment PSA Is Frequently Elevated Compared to Baseline PSA Following Hypofractionated Radiation Therapy
50. Utility of a Risk Priority Number in Managing Safety Event Reports in a Radiation Oncology Department
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.